Annals of Surgical Oncology, Vol 7, Issue 2 145-149, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects

K. A. Skinner, H. Silberman, B. Florentine, T. J. Lomis, F. Corso, D. Spicer and S. C. Formenti
Department of Surgery, Kenneth Norris Comprehensive Cancer Center, and the University of Southern California, Los Angeles 90033, USA.

INTRODUCTION: Approximately 15% of breast cancer patients present with large tumors that involve the skin, the chest wall, or the regional lymph nodes. Multimodality therapy is required, to provide the best chance for long-term survival. We have developed a regimen of paclitaxel, with concomitant radiation, as a primary therapy in patients with locally advanced breast cancer. METHODS: Eligible patients had locally advanced breast cancer (stage IIB or III). After obtaining informed consent, patients received paclitaxel (30 mg/m2 during 1 hour) twice per week for 8 weeks and radiotherapy to 45 Gy (25 fractions, at 180 cGy/fraction, to the breast and regional nodes). Patients then underwent modified radical mastectomy followed by postoperative polychemotherapy. RESULTS: Twenty-nine patients were enrolled. Of these, 28 were assessable for clinical response and toxicity, and 27 were assessable for pathological response. Objective clinical response was achieved in 89%. At the time of surgery, 33% had no or minimal microscopic residual disease. Chemoradiation-related acute toxicity was limited; however, surgical complications occurred in 41% of patients. CONCLUSIONS: Preoperative paclitaxel with radiotherapy is well tolerated and provides significant pathological response, in up to 33% of patients with locally advanced breast cancer, but with a significant postoperative morbidity rate.

This article has been cited by other articles:

				A. B. Chakravarthy, M. C. Kelley, B. McLaren, C. I. Truica, D. Billheimer, I. A. Mayer, A. M. Grau, D. H. Johnson, J. F. Simpson, R. D. Beauchamp, et al. Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1570 - 1576. [Abstract] [Full Text] [PDF]

				K. Liang, Y. Lu, W. Jin, K. K. Ang, L. Milas, and Z. Fan Sensitization of breast cancer cells to radiation by trastuzumab Mol. Cancer Ther., November 1, 2003; 2(11): 1113 - 1120. [Abstract] [Full Text] [PDF]

				S. C. Formenti, M. Volm, K. A. Skinner, D. Spicer, D. Cohen, E. Perez, A. C. Bettini, S. Groshen, C. Gee, B. Florentine, et al. Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial J. Clin. Oncol., March 1, 2003; 21(5): 864 - 870. [Abstract] [Full Text] [PDF]

				P. W. T. Pisters, R. A. Wolff, N. A. Janjan, K. R. Cleary, C. Charnsangavej, C. N. Crane, R. Lenzi, J. Nicolas Vauthey, J. E. Lee, J. L. Abbruzzese, et al. Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome J. Clin. Oncol., May 15, 2002; 20(10): 2537 - 2544. [Abstract] [Full Text] [PDF]

				A. G. Taghian, S. I. Assaad, A. Niemierko, I. Kuter, J. Younger, R. Schoenthaler, M. Roche, and S. N. Powell Risk of Pneumonitis in Breast Cancer Patients Treated With Radiation Therapy and Combination Chemotherapy With Paclitaxel J Natl Cancer Inst, December 5, 2001; 93(23): 1806 - 1811. [Abstract] [Full Text] [PDF]